Since its first identification as a human pathogen in the Wuhan province of China in December 2019, the SARS‐CoV‐2 virus, which causes COVID‐19, has become a global pandemic with immense medical and socio‐economic costs.
It is comforting, however, that previous data from several randomised, double‐blind, placebo‐controlled trials indicate that ALN‐RSV01 (a siRNA‐based drug) is safe to use and effective against respiratory syncytial virus infection.
, 
 Taken together, siRNA‐based therapeutics might be considered as an effective strategy to treat of COVID‐19.
Potential effects of siRNAs on silencing viral genes at the post‐transcriptional level in COVID‐19.